JPA Health led the full-scale launch of iDose TR by Glaukos, the first FDA-approved, micro-invasive, injectable treatment for glaucoma. Under the unifying HCP campaign platform “Shatter the Status Quo,” we developed a full suite of branded marketing assets to support HCP education, drive product awareness, and empower conversations within the optometry and ophthalmology community.

Highlights include:

• A comprehensive HCP website, designed and wireframed in Figma, in collaboration with external development partners
• A 16-page field sales aid used by Glaukos reps to educate HCPs on efficacy, safety, and procedure
• 5 targeted CRM emails introducing iDose and interventional glaucoma strategies
• A Launch Box and full conference suite including pull-up banners, table displays, and print brochures

Value Added

• Managed end-to-end creative workflows across a multidisciplinary team of 10+ creatives and stakeholders
• Developed agile timelines across 15+ simultaneous projects leading to a coordinated FDA launch
• Created centralized communication systems for cross-functional collaboration
• Oversaw Medical, Legal, and Regulatory (MLR) reviews, ensuring accurate and compliant materials
• Maintained project budgets and ensured all assets were routed, approved, and delivered on time

Results

• Drove awareness and education around interventional glaucoma
• Positioned iDose TR as a breakthrough solution for an underserved patient population
• Supported HCP education with robust digital and print materials
• Helped Glaukos become a trusted partner in the optometry and ophthalmology space
• Empowered patients and providers to explore new, minimally invasive options for glaucoma management